Chris Carswell
@PECjournal
Followers
2K
Following
2K
Media
194
Statuses
9K
Editor in Chief PharmacoEconomics. Past President ISPOR NZ Chapter, ex pharmacist, run and play the piano. UK expat in New Zealand. All views are my own
New Zealand
Joined January 2010
PharmacoEconomics has a Call For Papers for a themed issue on individual level models
link.springer.com
Pharmacoeconomics invites the submission of papers (original research, reviews, and tutorial pieces) on developing and using individual-level models for ...
0
0
1
A much needed reporting checklist for discrete choice experiments
link.springer.com
PharmacoEconomics - Reporting standards of discrete choice experiments (DCEs) in health have not kept pace with the growth of this method, with multiple reviews calling for better reporting to...
0
2
5
Seems to me the QALY is so entrenched in many countries it would take a huge effort to move away from it
0
0
1
Second, this solo editorial in Pharmacoeconomics, called "Making Models Fit for Purpose: the Importance of Ensuring Stakeholder Involvement". Also available free right here!
0
3
4
My 'Framework for the Fair Pricing of Medicines' has just been published as a Leading Article by Pharmacoeconomics. This framework proposes a number of advancements to existing approaches for specifying a 'cost-effectiveness threshold' for new medicines.
link.springer.com
PharmacoEconomics - As high-cost medicines put increasing pressure on public health care budgets, the need to identify ‘fair’ prices for medicines has never been greater. This paper...
1
8
24
Including carer outcomes in economic evaluation is important & can reveal unrecognised challenges in HTA decisions. One of these is where patient & carer QALYs point in different directions - work led by @davidjohnmott and colleagues @OHENews @HEU_UoB
https://t.co/c9tWwBmx3r
link.springer.com
PharmacoEconomics - The provision of informal (unpaid) care can impose significant ‘spillover effects’ on carers, and accounting for these effects is consistent with the efficiency and...
0
18
38
1/3 "Using Age-Specific Values for Pediatric HRQoL in CEA: Is There a Problem to Be Solved? If So, How?" available here👉 https://t.co/k4pT7cZiMp Really pleased this paper is out - hope it serves to progress the debate! @stolk_elly @MJSculpher @rich_norman @QUOKKA_Research
1
9
22
Happy to see this work published with @nancydevlin1 @tianxinpan @MJSculpher @markjit @donna_rowen Ben van Hout and @rich_norman! We highlight fundamental questions around the valuation of child health for use in economic evaluation that need to be resolved! #eq5dY @euroqol
1
10
31
Thread update on the QUOKKA project led by the brilliant @nancydevlin1 - huge output from this multi-university project on measuring and valuing child QoL
1/10 Time flies! @QUOKKA_Research is now in its 3rd and final year. Here's a thread with a quick overview of where we're at and what we'll be doing this year!
0
2
7
Terrible grammar is a key sign!
Academic publishing scams are getting very good, having had a paper published yesterday this came through soon after. If it wasn't for the terrible grammar I would have clicked on the link. Be careful out there! I was so pleased I'd been nominated!
0
0
1
Congratulations @dinaabushanab10 on this massive work on projecting the health and economic burden of CVD among people with type 2 diabetes @claremarquina @JedidiahMorton @PECjournal
link.springer.com
PharmacoEconomics - The aim was to project the health and economic outcomes of cardiovascular disease (CVD) among people with type 2 diabetes from Australian public healthcare and societal...
2
4
8
In preparation for my new class @HarrisPolicy, I asked ChatGPT: “How to conduct cost-effectiveness analysis (CEA)?” ChatGPT provides a very solid high-level summary, and I don’t think I can do a better job. Thoughts? @PeterNeumann11 @Basucally @AnkurFactorial @WrightCensored
2
4
31
At @ipha's conference. The Minister just mentioned Ireland's €45,000/QALY threshold and that there is an existing pathway for orphan drugs to exceed it. Interesting confirmation of the threshold and that it doesn't always apply.
1
1
9
@BCNHealth publishes a study reviewing economic evaluations and burden of disease studies of endometriosis #health #review #economic #evaluation #burden #disease #endometriosis #costs #indirect #productivity #losses
https://t.co/yR9pQgbgqg
0
3
2
Antimicrobial resistance or #AMR, as known in short, is a global health crisis. Find out how we're applying a new 'Netflix' style payment model to boost the antimicrobial pipeline, which has already assessed 2 new antimicrobial drugs⬇️ https://t.co/e7IFZtuzH8
link.springer.com
Applied Health Economics and Health Policy - The silent pandemic of antimicrobial resistance (AMR) is a global issue needing prompt attention. A comprehensive one-health approach across human and...
1
10
12
Long shot but are there any health economist out there would would review a journal paper for me? My last PhD by publication paper has been stuck in one journal for 5 months with no reviewers, I think it is now down to me to find one!
3
11
11
